Treatment of Sclerosing Mesenteritis: First-Line Anti-Inflammatory Management

Sclerosing mesenteritis (ICD-11 4A43.0 / ICD-10 K65.8) is managed with anti-inflammatory, disease-directed therapy as the first-line approach. Treatment selection is guided by the clinical picture, with the goal of achieving meaningful and sustained symptom improvement.

First-line therapy is anti-inflammatory and disease-directed. The most commonly used strategy centres on tamoxifen — used alone or in combination with a corticosteroid — though other agents may also be considered depending on individual circumstances.

The complete regimen, including combination options, maintenance considerations, and alternative agents, is covered in the full structured protocol.

The primary goals are improvement and clinical response of symptoms. Maximal response typically occurs around 4–6 months into treatment.